- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03899142
Pharmacokinetics of New HepBQuin
September 18, 2019 updated by: Prothya Biosolutions
Pharmacokinetics of HepBQuin Manufactured According to a New Production Process
Sanquin Plasma Products BV developed a new manufacturing process for the Quin plasma products in order to improve viral safety and to remove procoagulant activity.
Since the new manufacturing process will be the same for all Quin products, a clinical study with one of the Quin products is sufficient for marketing authorisation of all new Quin products.
HepBQuin will serve as model for all other Quin products.
Pharmacokinetic (PK) data are considered as a surrogate indicator of efficacy.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mannheim, Germany
- CRS Clinical Research Services Mannheim GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteers, male and female, aged 18 to 65 inclusive.
- Negative serology test for HBsAg, anti-HBs, and anti-HBc at screening.
- Body-mass index (BMI) of 18.5 to 32.0 kg/m2 (inclusive).
- Female volunteers must have a pregnancy test at screening.
- Willing to participate by signing the written signed informed consent form.
Exclusion Criteria:
- Vaccinated against Hepatitis B
- Having a Hepatitis B infection or suffered from a Hepatitis B infection in the past.
- Known with allergic reactions against human plasma, plasma products or blood products.
- A history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening.
- Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- Known with or having a history of arterial or venous thromboembolic events.
- Pre-existing risk factors for thrombotic events.
- Any clinically significant history of or current clinically significant other disease or disorder.
- Any clinically significant abnormality following the investigator's review of physical examination, and clinical laboratory tests obtained at screening.
- An abnormal pulse rate and/or blood pressure measurements at the screening visit.
- Pregnant or breast-feeding at screening or at Day 0
- Women of childbearing potential not using a highly effective method of birth.
- Any use of drugs or abuse within 3 months prior to screening and during study.
- Alcohol abuse within 3 months prior to screening and during study
- Participated in another interventional clinical trial a month before the start of the study, or having received an experimental drug during the previous 30 days.
- Having IgA deficiency with anti-IgA antibodies.
- Blood or plasma donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: human hepatitis B immunoglobulin
once, i.m.
|
intramuscular administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
half-life of anti-HBs antibodies
Time Frame: 84 days
|
Pharmacokinetics
|
84 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of adverse events
Time Frame: 84 days
|
Safety
|
84 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 20, 2019
Primary Completion (ACTUAL)
July 4, 2019
Study Completion (ACTUAL)
July 4, 2019
Study Registration Dates
First Submitted
March 29, 2019
First Submitted That Met QC Criteria
April 1, 2019
First Posted (ACTUAL)
April 2, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 19, 2019
Last Update Submitted That Met QC Criteria
September 18, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD2017.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on a human hepatitis B immunoglobulin solution for injection for intramuscular administration
-
University of PaviaCompleted
-
Laboratoire français de Fractionnement et de BiotechnologiesTFS Trial Form SupportCompletedMotor Neuron DiseaseSpain, United Kingdom, Italy, France
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de Salamanca; Spanish Clinical Research...CompletedHepatitis B | Hepatitis | Hepatitis, Viral, Human | Hepatitis B ImmunizationSpain
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
University of AlbertaOctapharmaRecruitingPrimary Immune Deficiency Disorder | Secondary Immune DeficiencyCanada
-
Xuanwu Hospital, BeijingGuidon Pharmaceutics Ltd.Not yet recruitingAcute Ischemic Stroke
-
DynPort Vaccine Company LLC, A GDIT CompanyWithdrawn
-
Biopharma Plasma LLCLviv National Medical University; Vinnitsa National Medical UniversityCompleted
-
CSL BehringCompletedPrimary Immune DeficiencyUnited States
-
Wei WangUnknownIntracranial Hemorrhage, HypertensiveChina